Search

Your search keyword '"Davendra Sohal"' showing total 82 results

Search Constraints

Start Over You searched for: Author "Davendra Sohal" Remove constraint Author: "Davendra Sohal" Publisher american society of clinical oncology (asco) Remove constraint Publisher: american society of clinical oncology (asco)
82 results on '"Davendra Sohal"'

Search Results

1. Analysis of HLA gene expression in patients with dMMR/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors

2. Impact of patient characteristics and treatment patterns on outcomes in potentially resectable pancreatic cancer (PC)

3. Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant

4. An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial

6. Fecal metagenome analysis in long-term survivors (LTS) of pancreas cancer

7. The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC)

8. Cancer Commons’ virtual tumor board program: A patient-centric advisory panel and real-world data registry

9. LRP1B and GRM3 expression in colorectal cancer

10. A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)

11. Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience

12. Predictors of clinical outcomes in patients undergoing curative treatment for esophageal or gastroesophageal junction adenocarcinoma

13. Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505

14. Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes

15. Globo H expression in metastatic colorectal cancer (CRC)

16. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

17. Molecular characterization of pancreatic cancers as seen in the SLUG gene revealing cancer progression

18. GDF15 expression in metastatic colorectal cancer

19. Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease

20. Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505

21. The landscape of MAP3K1/MAP2K4 alterations in gastrointestinal (GI) malignancies

22. Somatic alterations of NF1 in colorectal cancer

23. Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers

24. Profiling and prognostic implications of variants of unknown significance (VUS) in solid tumors

25. Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies

26. Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC)

27. The landscape of POLE variants in colorectal and endometrial tumors: Correlation with microsatellite instability (MSI) and tumor mutation burden (TMB)

28. The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC)

29. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)

30. A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA)

31. Real-world outcomes in pancreatic adenocarcinoma (PDAC) and persona types with implications for standard of care (SOC) therapy (Tx)

32. Microbiome signature of bile from pancreatic and biliary tract cancer patients: A pilot study

33. SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma

34. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors

35. Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx)

36. A multi-institutional study assessing prevalence of deleterious germline mutations in pancreatic cancer

37. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program

38. Genetic counseling (GC) and germline (GL) testing rates after adoption of an integrated clinical cancer genetics (CCG) approach to genomics tumor board (GTB)

39. Minority patient reported attitudes regarding tissue donation and participation in cancer research

40. Germline variants from paired somatic-germline testing in pancreatic cancer

41. Longitudinal precision oncology experience in solid tumors at the Cleveland Clinic

42. A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers

43. Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program

44. Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes

45. Multiomic molecular comparison of primary versus metastatic pancreatic tumors

46. SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma

47. Gauging public awareness and interest related to pancreatic cancer: An analysis of Google search volumes

48. Complement levels as predictors of survival in pancreatic adenocarcinoma

49. Precision oncology in pancreatobiliary cancers: A longitudinal study

50. Minority patient reported attitudes regarding tissue donation and participation in cancer research

Catalog

Books, media, physical & digital resources